Cantor Fitzgerald Analysts Lower Earnings Estimates for BCAX

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Bicara Therapeutics in a research note issued on Tuesday, November 11th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings of ($2.48) per share for the year, down from their prior estimate of ($2.19). The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2026 earnings at ($2.31) EPS.

Several other research firms have also commented on BCAX. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Piper Sandler assumed coverage on Bicara Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $36.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.67.

Bicara Therapeutics Trading Down 3.0%

Bicara Therapeutics stock traded down $0.44 during midday trading on Thursday, reaching $14.47. 57,103 shares of the stock traded hands, compared to its average volume of 598,536. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $24.09. The firm has a market cap of $792.67 million, a PE ratio of -6.46 and a beta of -0.76. The company has a 50-day simple moving average of $14.81 and a two-hundred day simple moving average of $12.55.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12).

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently modified their holdings of BCAX. CWM LLC acquired a new position in shares of Bicara Therapeutics in the 1st quarter valued at about $29,000. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Bicara Therapeutics during the first quarter valued at about $52,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period.

Insider Buying and Selling

In other Bicara Therapeutics news, insider David Raben sold 22,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $18.45, for a total value of $405,900.00. Following the sale, the insider owned 35,497 shares in the company, valued at approximately $654,919.65. This represents a 38.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Ivan Hyep sold 6,415 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $18.23, for a total transaction of $116,945.45. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,649,821.65. The trade was a 4.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 146,534 shares of company stock worth $2,682,012 in the last three months. Corporate insiders own 15.50% of the company’s stock.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.